Contrasting CASI Pharmaceuticals (NASDAQ:CASI) & Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ – Get Free Report) and CASI Pharmaceuticals (NASDAQ:CASI – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Profitability

This table compares Johnson & Johnson and CASI Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Johnson & Johnson 16.20% 31.64% 13.04%
CASI Pharmaceuticals -183.93% N/A -131.54%

Volatility & Risk

Johnson & Johnson has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Comparatively, CASI Pharmaceuticals has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500.

Institutional and Insider Ownership

69.6% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are owned by institutional investors. 0.2% of Johnson & Johnson shares are owned by insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Johnson & Johnson and CASI Pharmaceuticals”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Johnson & Johnson $94.19 billion 6.91 $26.80 billion $6.60 40.99
CASI Pharmaceuticals $26.85 million 0.10 -$39.26 million ($3.01) -0.07

Johnson & Johnson has higher revenue and earnings than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Johnson & Johnson and CASI Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Johnson & Johnson 0 8 17 1 2.73
CASI Pharmaceuticals 1 0 0 0 1.00

Johnson & Johnson presently has a consensus target price of $276.54, indicating a potential upside of 2.22%. Given Johnson & Johnson’s stronger consensus rating and higher possible upside, equities analysts clearly believe Johnson & Johnson is more favorable than CASI Pharmaceuticals.

Summary

Johnson & Johnson beats CASI Pharmaceuticals on 13 of the 15 factors compared between the two stocks.

About Johnson & Johnson

(Get Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

About CASI Pharmaceuticals

(Get Free Report)

CASI Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines, particularly for cancer and blood disorders. Its commercial and development activities have been centered largely on China. The company’s portfolio has included EVOMELA, a formulation of melphalan used in conditioning treatment for certain patients with multiple myeloma undergoing stem-cell transplantation. CASI has also pursued development and commercialization rights for additional oncology therapies, including CNCT19, an investigational CD19-directed CAR T-cell therapy.

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.